Source:http://linkedlifedata.com/resource/pubmed/id/17699452
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2007-8-16
|
| pubmed:abstractText |
The aims of this study were to assess the frequency and determinants of (1) treatment with angiotensin-converting enzyme inhibitors (ACE-I) and (2) progression to proteinuria in the presence of ACE-I treatment in patients with type 1 diabetes and microalbuminuria. A clinic-based cohort study of patients with type 1 diabetes was begun in 1991. The patients who were included in this study (n = 373) are the cohort members who received a diagnosis of microalbuminuria during a 2-yr baseline observation and were followed for 10 yr with frequent assessments of urinary albumin excretion and biennial examinations. Progression to proteinuria occurred when the median urinary albumin excretion during a 2-yr interval exceeded 299 mug/min. During the decade-long study, the proportion of patients who had a history of microalbuminuria and were treated with ACE-I rose from 17 to 67%. Patients who started this treatment had (on average) higher BP, higher urinary albumin excretion, and longer diabetes duration than those who did not. Microalbuminuria often progressed to proteinuria (6.3/100 person-years) in those who were treated. Poor glycemic control and elevated serum cholesterol were the major determinants/predictors of this progression. Although treatment with ACE-I increased during the past decade, it was not completely effective, because microalbuminuria progressed to proteinuria in many treated patients. Poor glycemic control and elevated serum cholesterol were the major determinants/predictors for progression while on ACE-I treatment. The mechanisms that are responsible for the frequent failure of ACE-I to prevent progression of microalbuminuria to proteinuria in a clinical setting are not clear.
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1555-905X
|
| pubmed:author |
pubmed-author:AschengrauAnnA,
pubmed-author:CupplesL AdrienneLA,
pubmed-author:FicocielloLinda HLH,
pubmed-author:FinkelsteinDianne MDM,
pubmed-author:GaciongZbigniewZ,
pubmed-author:Ignatowska-SwitalskaHalinaH,
pubmed-author:KrolewskiAndrzej SAS,
pubmed-author:PerkinsBruce ABA,
pubmed-author:SilvaKristen HKH,
pubmed-author:WarramJames HJH
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
461-9
|
| pubmed:dateRevised |
2007-12-3
|
| pubmed:meshHeading |
pubmed-meshheading:17699452-Adolescent,
pubmed-meshheading:17699452-Adult,
pubmed-meshheading:17699452-Albuminuria,
pubmed-meshheading:17699452-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:17699452-Blood Glucose,
pubmed-meshheading:17699452-Cholesterol,
pubmed-meshheading:17699452-Diabetes Mellitus, Type 1,
pubmed-meshheading:17699452-Diabetic Nephropathies,
pubmed-meshheading:17699452-Disease Progression,
pubmed-meshheading:17699452-Female,
pubmed-meshheading:17699452-Humans,
pubmed-meshheading:17699452-Male,
pubmed-meshheading:17699452-Multivariate Analysis,
pubmed-meshheading:17699452-Peptidyl-Dipeptidase A,
pubmed-meshheading:17699452-Proteinuria,
pubmed-meshheading:17699452-Risk Factors,
pubmed-meshheading:17699452-Treatment Failure,
pubmed-meshheading:17699452-Treatment Outcome
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
|
| pubmed:affiliation |
Research Division, Joslin Diabetes Center, Boston, Massachusetts 02215, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|